Literature DB >> 11898957

Recognition and management of hereditary hemochromatosis.

David J Brandhagen1, Virgil F Fairbanks, William Baldus.   

Abstract

Hereditary hemochromatosis is the most common inherited single-gene disorder in people of northern European descent. It is characterized by increased intestinal absorption of iron, with deposition of the iron in multiple organs. Previously, the classic description was combined diabetes mellitus, cutaneous hyperpigmentation and cirrhosis. Increasingly, however, hereditary hemochromatosis is being diagnosed at an earlier, less symptomatic stage. The diagnosis is based on a combination of clinical, laboratory and pathologic findings, including elevated serum transferrin saturation. Life expectancy is usually normal if phlebotomy is initiated before the development of cirrhosis or diabetes mellitus. Hereditary hemochromatosis is associated with mutations in the HFE gene. Between 60 and 93 percent of patients with the disorder are homozygous for a mutation designated C282Y. The HFE gene test is useful in confirming the diagnosis of hereditary hemochromatosis, screening adult family members of patients with HFE mutations and resolving ambiguities concerning iron overload.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11898957

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  14 in total

1.  Acquired hemochromatosis with pronounced pigment deposition of the upper eyelids.

Authors:  Anna H Chacon; Brian Morrison; Shasa Hu
Journal:  J Clin Aesthet Dermatol       Date:  2013-10

2.  Should we screen for hereditary hemochromatosis in healthy Lebanese: a pilot study.

Authors:  Rami A R Mahfouz; Doja S Sarieddine; Khalil M Charafeddine; Rabab N Abdul Khalik; Najwa K Cortas; Rose T Daher
Journal:  Mol Biol Rep       Date:  2011-05-07       Impact factor: 2.316

Review 3.  Molecular and clinical aspects of iron homeostasis: From anemia to hemochromatosis.

Authors:  Manfred Nairz; Günter Weiss
Journal:  Wien Klin Wochenschr       Date:  2006-08       Impact factor: 1.704

4.  Transmission Distortion of MCT1 rs1049434 among Polish Elite Athletes.

Authors:  Magdalena Dzitkowska-Zabielska; Aleksandra Bojarczuk; Małgorzata Borczyk; Marcin Piechota; Michał Korostyński; Jakub Grzegorz Adamczyk; Grzegorz Trybek; Myosotis Massidda; Paweł Cięszczyk
Journal:  Genes (Basel)       Date:  2022-05-12       Impact factor: 4.141

5.  A Case-Based Review of Iron Overload With an Emphasis on Porphyria Cutanea Tarda, Hepatitis C, C282Y Heterozygosity, and Coronary Artery Disease.

Authors:  Leila Hashemi; Robert Nisenbaum
Journal:  Fed Pract       Date:  2020-02

6.  Time to fatigue is increased in mouse muscle at 37 degrees C; the role of iron and reactive oxygen species.

Authors:  Trent F Reardon; David G Allen
Journal:  J Physiol       Date:  2009-05-26       Impact factor: 5.182

7.  Secondary haemochromatosis in a haemodialysis patient.

Authors:  Lu Cheng; Xi Tang; Ping Fu; Fang Liu
Journal:  Singapore Med J       Date:  2015-07       Impact factor: 1.858

8.  Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents.

Authors:  Etheresia Pretorius; Janette Bester; Natasha Vermeulen; Boguslaw Lipinski; George S Gericke; Douglas B Kell
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

9.  Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS).

Authors:  Janette Bester; Prashilla Soma; Douglas B Kell; Etheresia Pretorius
Journal:  Oncotarget       Date:  2015-11-03

10.  High ferritin levels have major effects on the morphology of erythrocytes in Alzheimer's disease.

Authors:  Janette Bester; Antoinette V Buys; Boguslaw Lipinski; Douglas B Kell; Etheresia Pretorius
Journal:  Front Aging Neurosci       Date:  2013-12-06       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.